Genetic evidence indicates that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may protect against Alzheimer’s disease and ischemic, cardioembolic, and general stroke subtypes across multiple ancestry groups, emjreviews.com reported. Researchers analyzed genome-wide association summary statistics to explore causal relationships between genetically proxied GLP-1RA effects and these neurological conditions.
Genetic Data Analyzed Across European, East Asian, and African Populations
To investigate whether the cardiometabolic benefits of GLP-1RAs extend to brain health, investigators conducted a two-sample Mendelian randomization study. The analysis utilized genetic datasets encompassing sample sizes from 3,026 to 1,812,017 individuals. Populations of European, East Asian, and African ancestry were included to assess whether protective associations remained consistent across diverse demographic groups.
Significant Risk Reductions Identified in European Cohorts
Among European participants, locus-based analyses revealed statistically significant protective associations for any stroke and ischemic stroke. These findings maintained significance after adjustment for multiple comparisons with a false discovery rate threshold of $p_{FDR} < 0.05$. Exploratory evaluations in East Asian and African cohorts pointed in a similar protective direction, though those specific ancestry groups did not reach statistical significance.
Cross-Ancestry Meta-Analyses Confirm Broad Protective Associations
When researchers combined evidence through cross-ancestry meta-analyses, four major protective associations met the $p_{FDR} < 0.05$ threshold. The analysis yielded odds ratios of 0.75 for any stroke, 0.72 for ischemic stroke, 0.55 for cardioembolic stroke, and 0.51 for Alzheimer’s disease. These aggregated results suggest consistent risk reductions, though authors note that genetically proxied effects do not directly establish the clinical outcomes of prescribing the medications.
Did you know? Mendelian randomization uses measured variants in DNA as instrumental variables to test causal relationships between a modifiable risk factor and a disease, mimicking the design of a randomized controlled trial.
Questions Concerning Genetic Insights Into GLP-1 Receptor Agonists
What specific datasets were utilized in the study?
Researchers used genome-wide association study summary statistics incorporating participant data ranging from 3,026 to 1,812,017 individuals.
Which stroke subtypes showed statistically significant reductions in European participants?
Locus-based analyses identified statistically significant protective associations for any stroke and ischemic stroke after adjustments for multiple comparisons.
What were the cross-ancestry meta-analysis odds ratios for Alzheimer’s disease?
The cross-ancestry meta-analysis yielded an odds ratio of 0.51 for Alzheimer’s disease, meeting the false discovery rate-adjusted significance threshold.
Keep reading